Doxorubicin SDZ 2 mg/ml (IV Infusion)
10 mg vial: ৳ 450.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Doxorubicin hydrochloride |
| Company | Sandoz a novartis division |
Indications
- Adjuvant chemotherapy for primary breast cancer
- Treatment of acute lymphoblastic leukemia
- Treatment of acute myeloblastic leukemia
- Treatment of Hodgkin lymphoma
- Treatment of Non-Hodgkin lymphoma
- Treatment of metastatic breast cancer
- Treatment of metastatic Wilms' tumor
- Treatment of metastatic neuroblastoma
- Treatment of metastatic soft tissue sarcoma
- Treatment of metastatic bone sarcomas
- Treatment of metastatic ovarian carcinoma
- Treatment of metastatic transitional cell bladder carcinoma
- Treatment of metastatic thyroid carcinoma
- Treatment of metastatic gastric carcinoma
- Treatment of metastatic bronchogenic carcinoma
Pharmacology
- Cytotoxic anthracycline topoisomerase IIinhibitor
- Nucleotide base intercalation activity
- Cell membrane lipid binding activity
- Inhibition of nucleotide replication
- Inhibition of DNA and RNA polymerases
- Formation of DNA-cleavable complexes
Dosage & Administration
- Single agent dose: 60 to 75 mg/m2 every 21 days
- Combination therapy dose: 40 to 75 mg/m2 every 21 to 28 days
- Administration via intravenous injection
- Administration via intravenous infusion
- Management of suspected extravasation
Interaction
- Major substrate of cytochrome P450 CYP3A4 and CYP2D6
- P-glycoprotein (P-gp) substrate
- Contraindicated concurrent use with inhibitors and inducers of CYP3A4, CYP2D6, or P-gp
- Contraindicated concurrent use with Trastuzumab
- Increased plasma-concentrations with prior Paclitaxel administration
Contraindications
- Severe myocardial insufficiency
- Recent myocardial infarction
- Severe persistent drug-induced myelosuppression
- Severe hepatic impairment
- Severe hypersensitivity reaction
Side Effects
- Alopecia
- Nausea
- Vomiting
- Cardiomyopathy
- Arrhythmias
- Secondary malignancies
- Extravasation and tissue necrosis
- Severe myelosuppression
- Tumor lysis syndrome
- Radiation sensitization and recall
Pregnancy & Lactation
- Pregnancy Category D
- Potential fetal harm
- Need for effective contraception during treatment
- Potential excretion in human milk
- Risk assessment for nursing infants
Use in Special Populations
- Pediatric use risk for late cardiovascular dysfunction
- Recommendation for long-term periodic cardiovascular monitoring in pediatric patients
- No overall differences in safety and effectiveness in geriatric patients
- Reduction in clearance in hepatic impaired patients
- Dose adjustment in severe hepatic impairment
Overdose Effects
- Extension of pharmacological action
- Fatal with single doses of 250 mg and 500 mg
- Acute myocardial degeneration
- Severe myelosuppression
- Delayed cardiac failure
Therapeutic Class
- Cytotoxic Chemotherapy
Reconstitution
- Preparation with 0.9% Sodium Chloride Injection or 5% Dextrose Injection
- Protection from light during preparation and infusion
- Visual inspection for precipitates, visible particles, and discoloration
- Precautions for handling and disposal
- Use of impervious gloves
- Immediate washing in case of skin or mucosa contact
Storage Conditions
- Dry place at 2°-8° C temperature
- Protection from light
- Avoid freezing
- Keep out of the reach of children
Related Brands
- Arodoxin 2 mg/ml (IV Infusion) - aristopharma-ltd
- Doxorubicin PhaRes 2 mg/ml (IV Infusion) - thymoorgan-pharmazie-gmbh-germany
- Doxotor 2 mg/ml (IV Infusion) - eskayef-pharmaceuticals-ltd
- Adribin 2 mg/ml (IV Infusion) - healthcare-pharmaceuticals-ltd
- Dobixin 2 mg/ml (IV Infusion) - drug-international-ltd